SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.
Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent Rexin-G® — the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of powerful biological anti-cancer agents that are exceedingly precise and highly selective for diseased tissues is currently in clinical development. Anti-cancer agents such as Rexin-G can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues. Representing the world’s first targeted genetic medicine proven to be both safe and effective in the clinic, Rexin-G is commercially available in the Philippines-for use in all solid tumors that are refractory to standard chemotherapy-and is currently in clinical trials in the USA for several types of cancer.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at http://www.epeiusbiotech.com.
For more information about Rexin-G, on-going clinical trials in the USA and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Erlinda M. Gordon, M.D., at email@example.com.
[tags]Epeius Biotechnologies Corporation, targeted gene delivery in vivo, Rexin-G patent[/tags]